Niagen Bioscience, Inc. (NAGE)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Sales, net | 31,117 | 30,481 | ||
| Cost of sales | 10,891 | 11,150 | ||
| Gross profit | 20,226 | 19,331 | ||
| Sales and marketing | 8,207 | 8,117 | ||
| Research and development | 1,567 | 1,258 | ||
| General and administrative | 7,267 | 5,184 | ||
| Total operating expenses | 17,041 | 14,559 | ||
| Operating income (loss) | 3,185 | 4,772 | ||
| Interest income, net | 552 | 459 | ||
| Income (loss) before provision for income taxes | 3,737 | 5,231 | ||
| Provision for income taxes | 128 | 168 | ||
| Net income (loss) | 3,609 | 5,063 | ||
| Basic (in dollar per share) | 0.05 | 0.07 | ||
| Basic (in shares) | 79,249,000 | 77,810,000 | ||
| Diluted (in dollar per share) | 0.04 | 0.06 | ||
| Diluted (in shares) | 86,241,000 | 83,232,000 | ||